- Home
- PBYI vs BGX Comparison
PBYI vs BGX Comparison
Compare PBYI & BGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- BGX
- Stock Information
- Founded
- PBYI 2010
- BGX 2010
- Country
- PBYI United States
- BGX United States
- Employees
- PBYI N/A
- BGX N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- BGX Trusts Except Educational Religious and Charitable
- Sector
- PBYI Health Care
- BGX Finance
- Exchange
- PBYI Nasdaq
- BGX Nasdaq
- Market Cap
- PBYI 153.2M
- BGX 163.6M
- IPO Year
- PBYI N/A
- BGX N/A
- Fundamental
- Price
- PBYI $2.92
- BGX $12.88
- Analyst Decision
- PBYI Strong Buy
- BGX
- Analyst Count
- PBYI 1
- BGX 0
- Target Price
- PBYI $7.00
- BGX N/A
- AVG Volume (30 Days)
- PBYI 416.5K
- BGX 67.9K
- Earning Date
- PBYI 11-07-2024
- BGX 01-01-0001
- Dividend Yield
- PBYI N/A
- BGX 10.34%
- EPS Growth
- PBYI 492.79
- BGX N/A
- EPS
- PBYI 0.47
- BGX N/A
- Revenue
- PBYI $243,569,000.00
- BGX N/A
- Revenue This Year
- PBYI N/A
- BGX N/A
- Revenue Next Year
- PBYI N/A
- BGX N/A
- P/E Ratio
- PBYI $6.26
- BGX N/A
- Revenue Growth
- PBYI 6.30
- BGX N/A
- 52 Week Low
- PBYI $2.23
- BGX $10.69
- 52 Week High
- PBYI $7.73
- BGX $12.44
- Technical
- Relative Strength Index (RSI)
- PBYI 47.45
- BGX 47.02
- Support Level
- PBYI $2.82
- BGX $12.99
- Resistance Level
- PBYI $3.12
- BGX $13.21
- Average True Range (ATR)
- PBYI 0.20
- BGX 0.14
- MACD
- PBYI -0.03
- BGX -0.01
- Stochastic Oscillator
- PBYI 14.71
- BGX 30.61
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About BGX Blackstone Long Short Credit Income Fund
Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It seeks to achieve its investment objectives by employing a dynamic long-short strategy in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first- and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.